Table 3.
Anti-inflammatory activities of additional H. inuloides metabolites.
| Compound (1 μmol/ear) |
Edema | % |
|---|---|---|
| (mg, average SE) | Inhibition | |
| Negative control | 12.07 | — |
| 1 | 10.50 ± 0.99 | 5.41 |
| 2 | 1.85 ± 0.52 | 83.33** |
| 4 | 5.27 ± 0.70 | 65.73** |
| 5 | 9.80 ± 0.36 | 7.98 |
| 7 | 7.30 ± 1.15 | 38.86** |
| 9 | 7.57 ± 0.45 | 36.63** |
| 13 | 11.87 ± 0.66 | −11.42 |
| 14 | 11.07 ± 1.15 | 11.06 |
| 15 | 13.60 ± 0.70 | −13.90 |
| 16 | 3.73 ± 1.62 | 66.44** |
| 17 | 9.07 ± 0.70 | 19.46 |
| 18 | 13.17 ± 0.51 | 13.57 |
| Indomethacin (0.31 μ mol) | 61.90** |
The data represent the mean of three animals ± the standard error of the mean. All the compounds were tested at 1 μmol/ear doses. The results were analyzed by ANOVA. Student's t-test was used to compare outcomes between experimental and control groups. * P < 0.05 versus reference drug.